Last updated: 2026-09-07 21:37:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Intensity Therapeutics, Inc. (INTS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $4,07, with a market capitalization of $13,39M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,51 to $43,50. This page covers its latest market performance, valuation, price trends and company information.
$13,39M | |
$4,03 | |
$286,00 | |
$3,51 | |
$4,00 | |
3,45K | |
42,56K | |
-- | |
$43,50 | |
$3,51 | |
-- | |
-- |
Intensity Therapeutics, Inc. (INTS) last closed at $4,00 as of 2026-09-04 23:48:00, unchanged from the previous close of $4,00.
During the latest regular trading session, INTS traded between $3,51 and $286,00, with a volume of 3,45K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Intensity Therapeutics, Inc. (INTS) moved from $4,27 to $4,07, representing a decline of 4,80% ($0,20).
The stock traded between $3,99 and $4,70 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 22,35 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1,4%
INTS is currently trading at $4,07, placing it 1,4% of the way from its 52-week low of $3,51 to its 52-week high of $43,50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Intensity Therapeutics, Inc. (INTS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.